#1 PRESCRIBED MIGRAINE TREATMENT IN ITS CLASS SINCE 8/6/2021*

For the acute treatment of migraine with or without aura and the preventive treatment of episodic migraine in adults

Nurtec® ODT (rimegepant) orally disintegrating tablets 75 mg

American Headache Society Goals for Acute Treatment of Migraine

The 2021 American Headache Society (AHS) Consensus Statement recommends 6 goals for acute treatment of migraine[1]

- Rapid and consistent freedom from pain and associated symptoms, especially the most bothersome symptom, without recurrence
- Optimal self-care and reduced subsequent use of resources (eg, emergency room visits, diagnostic imaging, clinician and ambulatory infusion center visits)
- Minimal need for repeat dosing or rescue medications
- Restored ability to function
- Minimal or no adverse events
- Cost considerations

Suboptimal acute treatment is associated with higher migraine-related disability and risk of disease progression[1]

Consider Nurtec ODT as an acute treatment option for your patients with migraine

CGRP=calcitonin gene-related peptide.

*Per IQVIA as oral brand in class (oral CGRP receptor antagonists): number one prescribed and number one in new prescriptions, since 8/6/21. Data current as of 3/31/24.

SELECT IMPORTANT SAFETY INFORMATION

Contraindications: Hypersensitivity to Nurtec ODT or any of its components.

Warnings and Precautions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included dyspnea and rash and can occur days after administration.

Please see additional Important Safety Information on the next page and click for full Prescribing Information.

#1
PRESCRIBED MIGRAINE TREATMENT IN ITS CLASS
SINCE 8/6/2021*

Pfizer

Learn how Nurtec ODT may help your patients with migraine.

*Per IQVIA as oral brand in class (oral CGRP receptor antagonists): number one prescribed and number one in new prescriptions, since 8/6/21. Data current as of 3/31/24.

INDICATIONS

Nurtec ODT is indicated in adults for the:

- acute treatment of migraine with or without aura
- preventive treatment of episodic migraine

IMPORTANT SAFETY INFORMATION

Contraindications: Hypersensitivity to Nurtec ODT or any of its components.

Warnings and Precautions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included dyspnea and rash and can occur days after administration.

Adverse Reactions: The most common adverse reactions were nausea (2.7% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo) and abdominal pain/dyspepsia (2.4% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo). Hypersensitivity, including dyspnea and rash, occurred in less than 1% of patients treated with Nurtec ODT.

Drug Interactions: Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4, or strong or moderate inducers of CYP3A. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4 or potent inhibitors of P-gp.

Use in Specific Populations: *Pregnancy:* It is not known if Nurtec ODT can harm an unborn baby. *Lactation:* The transfer of rimegepant into breastmilk is low (<1%). *Hepatic impairment:* Avoid use of Nurtec ODT in persons with severe hepatic impairment. *Renal impairment:* Avoid use in patients with end-stage renal disease.

June 2024. PP-NNT-USA-3640.

Click for full Prescribing Information.

Reference: 1. Ailani J, Burch RC, Robbins MS; the Board of Directors of the American Headache Society. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. *Headache*. 2021;61:1021-1039.

Nurtec® ODT
(rimegepant)
orally disintegrating tablets 75 mg